Details
Stereochemistry | ACHIRAL |
Molecular Formula | C18H30O2 |
Molecular Weight | 278.4296 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 3 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O
InChI
InChIKey=VZCCETWTMQHEPK-QNEBEIHSSA-N
InChI=1S/C18H30O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18(19)20/h6-7,9-10,12-13H,2-5,8,11,14-17H2,1H3,(H,19,20)/b7-6-,10-9-,13-12-
Molecular Formula | C18H30O2 |
Molecular Weight | 278.4296 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 3 |
Optical Activity | NONE |
DescriptionSources: http://www.allthingscanid.org/EveningPrimroseOil.pdf
Sources: http://www.allthingscanid.org/EveningPrimroseOil.pdf
Gamolenic acid also known as gamma-lonolenic acid is a natural component of Oenothera biennis L. (Evening Primrose). Gamolenic acid was used for the treatment of breast painand atopic dermatitis in Europe, although now the drug is withdrawn from the market (there is no safety issue associated with the withdrawal of the licences). The mechanism of action of gamolenic acid is connected with its interaction with prostanoid pathway.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: GO:0006692 Sources: http://www.allthingscanid.org/EveningPrimroseOil.pdf |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | EFAMAST Approved UseUnknown |
|||
Primary | EPOGAM Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
gamma-Carboxyglutamate excretion and warfarin therapy. | 1979 May |
|
Is the origin of atopy linked to deficient conversion of omega-6-fatty acids to prostaglandin E1? | 1989 Sep |
|
Evening primrose oil (Epogam) in the treatment of chronic hand dermatitis: disappointing therapeutic results. | 1996 |
|
Plasma and tissue levels of lipids, fatty acids and plasma carnitine in neonates receiving a new fat emulsion. | 1997 Jun |
|
Modulation in vitro of human natural cytotoxicity, lymphocyte proliferative response to mitogens and cytokine production by essential fatty acids. | 1997 Oct |
|
Evidence for age-related differences in the fatty acid composition of human adipose tissue, independent of diet. | 1997 Sep |
|
Characterization of arachidonic acid-induced apoptosis. | 1999 |
|
Evidence for direct binding of fatty acids and eicosanoids to human peroxisome proliferators-activated receptor alpha. | 1999 Jul 14 |
|
Identification of the major intestinal fatty acid transport protein. | 1999 Sep |
|
Metabolism of polyunsaturated fatty acids by skin epidermal enzymes: generation of antiinflammatory and antiproliferative metabolites. | 2000 Jan |
|
The influence of polyunsaturated fatty acids on probiotic growth and adhesion. | 2001 Jan 15 |
|
Polyunsaturated fatty acids in maternal diet, breast milk, and serum lipid fatty acids of infants in relation to atopy. | 2001 Jul |
|
Eicosapentaenoic acid and docosahexaenoic acid from fish oils: differential associations with lipid responses. | 2002 May |
|
Characterization of a heart-specific fatty acid transport protein. | 2003 May 2 |
|
Fatty acid profiles, antioxidant status, and growth of preterm infants fed diets without or with long-chain polyunsaturated fatty acids. A randomized clinical trial. | 2003 Oct |
|
A retinoid X receptor (RXR)-selective retinoid reveals that RXR-alpha is potentially a therapeutic target in breast cancer cell lines, and that it potentiates antiproliferative and apoptotic responses to peroxisome proliferator-activated receptor ligands. | 2004 |
|
Metabolic consequences of hypoxia from birth and dexamethasone treatment in the neonatal rat: comprehensive hepatic lipid and fatty acid profiling. | 2004 Nov |
|
Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120. | 2005 Jan |
|
Synergistic regulation of endothelial tight junctions by antioxidant (Se) and polyunsaturated lipid (GLA) via Claudin-5 modulation. | 2006 Aug 1 |
|
Induction of apoptosis in K562/ADM cells by gamma-linolenic acid involves lipid peroxidation and activation of caspase-3. | 2006 Aug 25 |
|
Conjugated linoleic acid, unlike other unsaturated fatty acids, strongly induces glutathione synthesis without any lipoperoxidation. | 2006 Nov |
|
TRPV1 is a novel target for omega-3 polyunsaturated fatty acids. | 2007 Jan 15 |
|
Screening of 397 chemicals and development of a quantitative structure--activity relationship model for androgen receptor antagonism. | 2008 Apr |
|
Antimicrobial activity of n-6, n-7 and n-9 fatty acids and their esters for oral microorganisms. | 2010 Aug |
|
Antineoplastic effects of gamma linolenic Acid on hepatocellular carcinoma cell lines. | 2010 Jul |
|
JNK implication in adipocyte-like cell death induced by chemotherapeutic drug cisplatin. | 2015 Feb |
Sample Use Guides
In Vivo Use Guide
Sources: http://www.allthingscanid.org/EveningPrimroseOil.pdf
4–6 capsules (500 mg) twice daily (40 mg gamolenic acid per capsule).
Route of Administration:
Oral
The cells were treated with various concentrations of gamolenic acid for 24 h and cell viability was determined by the MTT assay. Treatment of the K562 cells with gamolenic concentrations less
than 50 uM did not inhibit cell viability, but treatment
with concentrations of 50-150 uM caused a dosedependent decrease, and the concentration of gamolenic acid inducing 50% cell inhibition (IC50) after 24 h was 101.59 uM.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:13:52 GMT 2023
by
admin
on
Fri Dec 15 15:13:52 GMT 2023
|
Record UNII |
78YC2MAX4O
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
FDA ORPHAN DRUG |
82994
Created by
admin on Fri Dec 15 15:13:52 GMT 2023 , Edited by admin on Fri Dec 15 15:13:52 GMT 2023
|
||
|
NCI_THESAURUS |
C2563
Created by
admin on Fri Dec 15 15:13:52 GMT 2023 , Edited by admin on Fri Dec 15 15:13:52 GMT 2023
|
||
|
DSLD |
1290 (Number of products:674)
Created by
admin on Fri Dec 15 15:13:52 GMT 2023 , Edited by admin on Fri Dec 15 15:13:52 GMT 2023
|
||
|
WHO-VATC |
QD11AX02
Created by
admin on Fri Dec 15 15:13:52 GMT 2023 , Edited by admin on Fri Dec 15 15:13:52 GMT 2023
|
||
|
NCI_THESAURUS |
C68403
Created by
admin on Fri Dec 15 15:13:52 GMT 2023 , Edited by admin on Fri Dec 15 15:13:52 GMT 2023
|
||
|
WHO-ATC |
D11AX52
Created by
admin on Fri Dec 15 15:13:52 GMT 2023 , Edited by admin on Fri Dec 15 15:13:52 GMT 2023
|
||
|
WHO-ATC |
D11AX02
Created by
admin on Fri Dec 15 15:13:52 GMT 2023 , Edited by admin on Fri Dec 15 15:13:52 GMT 2023
|
||
|
WHO-VATC |
QD11AX52
Created by
admin on Fri Dec 15 15:13:52 GMT 2023 , Edited by admin on Fri Dec 15 15:13:52 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
618453
Created by
admin on Fri Dec 15 15:13:52 GMT 2023 , Edited by admin on Fri Dec 15 15:13:52 GMT 2023
|
ALTERNATIVE | |||
|
DB13854
Created by
admin on Fri Dec 15 15:13:52 GMT 2023 , Edited by admin on Fri Dec 15 15:13:52 GMT 2023
|
PRIMARY | |||
|
1276
Created by
admin on Fri Dec 15 15:13:52 GMT 2023 , Edited by admin on Fri Dec 15 15:13:52 GMT 2023
|
PRIMARY | |||
|
C68369
Created by
admin on Fri Dec 15 15:13:52 GMT 2023 , Edited by admin on Fri Dec 15 15:13:52 GMT 2023
|
PRIMARY | |||
|
100000084515
Created by
admin on Fri Dec 15 15:13:52 GMT 2023 , Edited by admin on Fri Dec 15 15:13:52 GMT 2023
|
PRIMARY | |||
|
CHEMBL464982
Created by
admin on Fri Dec 15 15:13:52 GMT 2023 , Edited by admin on Fri Dec 15 15:13:52 GMT 2023
|
PRIMARY | |||
|
SUB07879MIG
Created by
admin on Fri Dec 15 15:13:52 GMT 2023 , Edited by admin on Fri Dec 15 15:13:52 GMT 2023
|
PRIMARY | |||
|
m6832
Created by
admin on Fri Dec 15 15:13:52 GMT 2023 , Edited by admin on Fri Dec 15 15:13:52 GMT 2023
|
PRIMARY | Merck Index | ||
|
25605
Created by
admin on Fri Dec 15 15:13:52 GMT 2023 , Edited by admin on Fri Dec 15 15:13:52 GMT 2023
|
PRIMARY | |||
|
28661
Created by
admin on Fri Dec 15 15:13:52 GMT 2023 , Edited by admin on Fri Dec 15 15:13:52 GMT 2023
|
PRIMARY | |||
|
283564
Created by
admin on Fri Dec 15 15:13:52 GMT 2023 , Edited by admin on Fri Dec 15 15:13:52 GMT 2023
|
PRIMARY | |||
|
D017965
Created by
admin on Fri Dec 15 15:13:52 GMT 2023 , Edited by admin on Fri Dec 15 15:13:52 GMT 2023
|
PRIMARY | |||
|
DTXSID7046170
Created by
admin on Fri Dec 15 15:13:52 GMT 2023 , Edited by admin on Fri Dec 15 15:13:52 GMT 2023
|
PRIMARY | |||
|
2834
Created by
admin on Fri Dec 15 15:13:52 GMT 2023 , Edited by admin on Fri Dec 15 15:13:52 GMT 2023
|
PRIMARY | |||
|
5280933
Created by
admin on Fri Dec 15 15:13:52 GMT 2023 , Edited by admin on Fri Dec 15 15:13:52 GMT 2023
|
PRIMARY | |||
|
78YC2MAX4O
Created by
admin on Fri Dec 15 15:13:52 GMT 2023 , Edited by admin on Fri Dec 15 15:13:52 GMT 2023
|
PRIMARY | |||
|
78YC2MAX4O
Created by
admin on Fri Dec 15 15:13:52 GMT 2023 , Edited by admin on Fri Dec 15 15:13:52 GMT 2023
|
PRIMARY | |||
|
506-26-3
Created by
admin on Fri Dec 15 15:13:52 GMT 2023 , Edited by admin on Fri Dec 15 15:13:52 GMT 2023
|
PRIMARY | |||
|
GAMMA-LINOLENIC ACID
Created by
admin on Fri Dec 15 15:13:52 GMT 2023 , Edited by admin on Fri Dec 15 15:13:52 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> CONSTITUENT ALWAYS PRESENT | |||
|
PARENT -> CONSTITUENT ALWAYS PRESENT |
USP
|
||
|
LIPID -> FATTY ACID |
U.S produced rice oil. Values are % of composition.
|
||
|
SALT/SOLVATE -> PARENT | |||
|
PARENT -> CONSTITUENT ALWAYS PRESENT | |||
|
PARENT -> CONSTITUENT ALWAYS PRESENT |
USP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |